Market closedADR

Zai Lab/$ZLAB

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Zai Lab

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Ticker

$ZLAB
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Shanghai, China

Employees

2,175
Website
www.zailaboratory.com

Zai Lab Metrics

BasicAdvanced
$2.6B
-
-$2.78
0.98
-

$2.6B

0.98

$32.50

$13.48

612K

3.006

2.394

0.916

18.825

-250.52%

-20.84%

-34.98%

6.659

3.58

3.9

-10.836

35.01%

-11.07%

45.61%

-23.71%

What the Analysts think about Zai Lab

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.

Zai Lab Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Zai Lab Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Zai Lab News

AllArticlesVideos
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

Business Wire·5 days ago
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

Business Wire·5 days ago
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

Business Wire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ZLAB

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Zai Lab stock?

Zai Lab (ZLAB) has a market cap of $2.6B as of January 15, 2025.

What is the P/E ratio for Zai Lab stock?

The price to earnings (P/E) ratio for Zai Lab (ZLAB) stock is 0 as of January 15, 2025.

Does Zai Lab stock pay dividends?

No, Zai Lab (ZLAB) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Zai Lab dividend payment date?

Zai Lab (ZLAB) stock does not pay dividends to its shareholders.

What is the beta indicator for Zai Lab?

Zai Lab (ZLAB) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.